| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01:22 | F. Hoffmann-La Roche Ltd: Roche's fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMS | 39 | GlobeNewswire (Europe) | Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib compared to teriflunomide in reducing relapses and brain lesions in relapsing multiple sclerosis... ► Artikel lesen | |
| 01:18 | Pharmather Holdings Ltd: Pharmather hopes programs benefit from executive order | 2 | Stockwatch | ||
| 00:03 | CYCLOPHARM LIMITED: Change in substantial holding | - | ASX | ||
| 00:00 | Merck gains approval of HIV drug regimen Idvynso | 3 | Seeking Alpha | ||
| Di | Merck Once-Daily HIV Treatment Idvynso Approved by FDA | 4 | Contract Pharma | ||
| Di | Eli Lilly terminates license agreement with Rigel over ocadusertib | 3 | Seeking Alpha | ||
| Di | Avicanna Inc: Avicanna to hold AGSM May 7 | 3 | Stockwatch | ||
| Di | Medpace Q1 2026 Earnings Preview | 1 | Seeking Alpha | ||
| Di | AMPLIA THERAPEUTICS LIMITED: ACCENT Trial Mature Data Presented at AACR Conference | - | ASX | ||
| Di | POLYNOVO LIMITED: Appointment of Dr Marthe DOmbrain as Chief Scientific Offic | - | ASX | ||
| Di | Univest Securities closes $40m equity line for PMGC Holdings | 1 | Investing.com | ||
| Di | Wechsel im Verwaltungsrat von Xeris Biopharma: Jeffrey Sherman tritt 2026 ab | 1 | Investing.com Deutsch | ||
| Di | Red Light Holland Corp: Red Light notes psychedelic policy shift for Kala Bio | 2 | Stockwatch | ||
| Di | VEXT Science, Inc.: Vext Announces Revised Date for Q4 and Fiscal 2025 Financial Results Release | 223 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - April 21, 2026) - Vext Science, Inc. (CSE: VEXT) (OTCQX: VEXTF) ("Vext" or the "Company") a U.S.-based cannabis operator in Arizona and Ohio, today... ► Artikel lesen | |
| Di | Amazon shakes GLP-1 race as Eli Lilly, Novo Nordisk stocks fall | 20 | iNVEZZ.com | ||
| Di | Trulieve Cannabis Corp. - 8-K, Current Report | 1 | SEC Filings | ||
| Di | Journey Medical Corp - 8-K, Current Report | - | SEC Filings | ||
| Di | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Report First Quarter Financial Results on May 5, 2026 | 212 | PR Newswire | DUBLIN, April 21, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced its 2026 first quarter financial results will be reported on Tuesday, May 5, 2026, after the... ► Artikel lesen | |
| Di | XORTX Therapeutics Inc (4): XORTX cures minimum bid deficiency on Nasdaq | 4 | Stockwatch | ||
| Di | Wave Life Sciences seeks court approval for Singapore-to-US move | 2 | Investing.com |
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | Aktuelle Nachrichten | |||
|---|---|---|---|---|---|---|---|
| ELI LILLY | 18 | 125 | -1,37 % | Aktien unter Druck, aber mit deutlichem Potenzial - dynaCERT Inc., Eli Lilly, K+S, Novo Nordisk | Am Wochenende scheiterten die Verhandlungen zur Beendigung des Krieges zwischen den USA und dem Iran, doch schon Ende dieser Woche soll es bereits eine nächste Verhandlungsrunde geben. Das machte sich... ► Artikel lesen | ||
| MERCK & CO | 17 | 43 | -3,48 % | Merck & Co. (MRK): Die Bullen lauern an der 20-Tagelinie! | Konsolidierung auf hohem Niveau! Rückblick Die Aktie von Merck befindet sich in einer Korrekturphase innerhalb eines starken Aufwärtstrends. Der Markt "atmet durch", nachdem die Kurse schnell gestiegen... ► Artikel lesen | ||
| NOVO NORDISK | 14 | 40 | -2,18 % | Amazon shakes GLP-1 race as Eli Lilly, Novo Nordisk stocks fall | |||
| BAYER | 13 | 36 | -3,22 % | EQS-Media: YOC AG: Relevanz statt Beschallung - Wie Bayer mit integrierter Husten-KI Markenkampagnen mit Mehrwert schafft | EQS-Media / 16.04.2026 / 07:59 CET/CEST
Berlin, 16. April 2026 - Bayer Vital hat mit dem Ad Tech Unternehmen YOC AG eine daten- und KI-basierte Kampagne umgesetzt und über die VIS.X Plattform... ► Artikel lesen | ||
| ASTRAZENECA | 12 | 22 | -1,82 % | Astra Zeneca kritisiert geplante Kürzungen im Gesundheitssystem | Cambridge - Der britische Hersteller Astra Zeneca hat vor möglichen Folgen der Kürzungen im deutschen Gesundheitssystem gewarnt. Man könne ab dem kommenden Jahr keine neuen Arzneien aus der Forschung... ► Artikel lesen | ||
| ROCHE | 8 | 20 | -2,27 % | F. Hoffmann-La Roche Ltd: Roche's ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD | Phase III METEOROID study met its primary endpoint in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)MOGAD is a rare autoimmune disease of the central nervous system... ► Artikel lesen | ||
| SSY GROUP | 8 | - | - | SSY Group: Furosemide Approved in China as Active Pharmaceutical Ingredient for Marketed Formulations | |||
| PFIZER | 7 | 92 | -0,24 % | Astellas, Pfizer Say FDA Grants Priority Review To SBLA For PADCEV Plus Keytruda | TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY) and Pfizer Inc. (PFE) on Monday said the U.S. Food and Drug Administration has granted Priority Review for a supplemental Biologics License Application... ► Artikel lesen | ||
| COMPASS PATHWAYS | 5 | 11 | -1,88 % | Psychedelika vor Durchbruch: Kurssprung bei Compass Pathways und ein starkes Signal für TEQ Capital | |||
| EISAI | 5 | 5 | -2,03 % | Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC) | TOKYO and RAHWAY, N.J., Apr 21, 2026 - (JCN Newswire) - Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada), and Eisai (Headquarters: Tokyo, CEO: Haruo Naito) today... ► Artikel lesen |
| Unternehmen / Aktien | Aktueller Kurs | Ø Kursziel (Euro) | Potential (Euro) | kaufen | halten | verkaufen | |||
|---|---|---|---|---|---|---|---|---|---|
| ELI LILLY AND COMPANY | 770,60 | 968,78 | +26 % | 1 | - | - | |||
| SCHOTT PHARMA AG & CO KGAA | 15,540 | 18,70 | +20 % | 3 | 9 | - | |||
| MERCK KGAA | 117,50 | 140,40 | +19 % | 10 | 7 | - | |||
| SANOFI SA | 80,94 | 94,57 | +17 % | 9 | 15 | - | |||
| ASTRAZENECA PLC | 167,55 | 191,96 | +15 % | 25 | 1 | 6 | |||
| ROCHE HOLDING AG PS | 341,83 | 383,19 | +12 % | 11 | 17 | 4 | |||
| BAYER AG | 40,030 | 44,71 | +12 % | 25 | 10 | 1 | |||
| NOVO NORDISK A/S | 33,620 | 37,47 | +11 % | 11 | 31 | 2 | |||
| PFIZER INC | 23,300 | 24,61 | +6 % | 1 | 4 | - | |||
| NOVARTIS AG | 126,86 | 129,57 | +2 % | 5 | 11 | 3 | |||
| GSK PLC | 23,930 | 22,73 | -5 % | 5 | 9 | 15 | |||
| DOCMORRIS AG | 7,860 | 6,95 | -12 % | 4 | 8 | 5 | |||
| DERMAPHARM HOLDING SE | 45,900 | 34 | -26 % | - | 2 | - |